Results: Three phase 1b trials with 40 patients and three phase 2 trials with 352 patients studying TLR8 and TLR9 agonists in combination with other treatment regimens for HNSCC were included. This evidence concerns the gene TLR9 and head and neck squamous cell carcinoma.